This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Farley, J. Articles by Birrer, M. J. Search for Related Content PubMed PubMed Citation Articles by Farley, J. Articles by Birrer, M. J.

Cyclin E Expression Is a Significant Predictor of Survival in Advanced, Suboptimally Debulked Ovarian Epithelial Cancers: A Gynecologic Oncology Group Study¹

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Tripler Army Medical Center (TAMC, HI), 96859-5000 [J. F.]; Department of Radiological Health Sciences, Colorado State University, Fort Collins, Colorado 80523-1673 [L. M. S.]; Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, New York 14263 [K. M. D., E. S.]; Norton Healthcare, Inc., Clinical Pathology Associates, Louisville, Kentucky 40207 [D. O.]; Vysis, Inc., Downers Grove, Illinois 60515 [L. E. M., B. H.]; and Cell and Cancer Biology Department, Medicine Branch, Division of Clinical Sciences, National Cancer Institute, Rockville, Maryland 20850 [M. J. B.]

Cyclin E is a key regulator of the G₁-S transition. Abnormalities in cyclinE expression have been related to survival in a variety of cancers. Thisstudy evaluated the prognostic relevance of cyclin E in human ovarian cancer. Immunohistochemical expression of cyclin E was evaluated in 139 advanced, suboptimally debulked epithelial ovarian cancer specimens from patients treated on Gynecologic Oncology Group protocol 111. High cyclin E protein expression (40% cyclin E positive tumor cells) was seen in 62 (45%) of the advanced, suboptimally debulked ovarian cancer patients. Expression of cyclin E was not associated with age, race, stage, grade, cell type, or amount of residual disease. High verses low cyclin E expression was associated with a shorter median survival (29 ± 2 versus 35 ± 3 months) and worse overall survival (P < 0.05). Univariate and multivariate regression analyses revealed that high relative to low cyclin E was associated with a 40–50% increase in the risk of death (hazard rate, P 0.05). Fluorescence in situ hybridization was used in a subset of 20 cases to examine cyclin E gene amplification. Eight of 10 cases with high cyclin E expression exhibited amplification of the cyclin E gene, whereas only 1 of 10 cases with low expression displayed gene amplification (P < 0.006). High cyclin E expression was an independent poor prognostic factor for patients with advanced ovarian cancer, and it was associated with amplification of the cyclin E gene.

This article has been cited by other articles:

				J. M. Schildkraut, P. G. Moorman, A. E. Bland, S. Halabi, B. Calingaert, R. Whitaker, P. S. Lee, T. Elkins-Williams, R. C. Bentley, J. R. Marks, et al. Cyclin E Overexpression in Epithelial Ovarian Cancer Characterizes an Etiologic Subgroup Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 585 - 593. [Abstract] [Full Text] [PDF]

				I. Bedrosian, C. Lee, S. L. Tucker, S. L. Palla, K. Lu, and K. Keyomarsi Cyclin E Associated Kinase Activity Predicts Response to Platinum-Based Chemotherapy Clin. Cancer Res., August 15, 2007; 13(16): 4800 - 4806. [Abstract] [Full Text] [PDF]

				P. C.K. Leung and J.-H. Choi Endocrine signaling in ovarian surface epithelium and cancer Hum. Reprod. Update, March 1, 2007; 13(2): 143 - 162. [Abstract] [Full Text] [PDF]

				B. Davidson, Z. Zhang, L. Kleinberg, M. Li, V. A. Florenes, T.-L. Wang, and I.-M. Shih Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma. Clin. Cancer Res., October 15, 2006; 12(20): 5944 - 5950. [Abstract] [Full Text] [PDF]

				J. T. Park, M. Li, K. Nakayama, T.-L. Mao, B. Davidson, Z. Zhang, R. J. Kurman, C. G. Eberhart, I.-M. Shih, and T.-L. Wang Notch3 gene amplification in ovarian cancer. Cancer Res., June 15, 2006; 66(12): 6312 - 6318. [Abstract] [Full Text] [PDF]

				I. H. Koumakpayi, J.-S. Diallo, C. Le Page, L. Lessard, M. Gleave, L. R. Begin, A.-M. Mes-Masson, and F. Saad Expression and Nuclear Localization of ErbB3 in Prostate Cancer. Clin. Cancer Res., May 1, 2006; 12(9): 2730 - 2737. [Abstract] [Full Text] [PDF]

				T. Bonome, J.-Y. Lee, D.-C. Park, M. Radonovich, C. Pise-Masison, J. Brady, G. J. Gardner, K. Hao, W. H. Wong, J. C. Barrett, et al. Expression Profiling of Serous Low Malignant Potential, Low-Grade, and High-Grade Tumors of the Ovary Cancer Res., November 15, 2005; 65(22): 10602 - 10612. [Abstract] [Full Text] [PDF]

				A. M. Eder, X. Sui, D. G. Rosen, L. K Nolden, K. W. Cheng, J. P. Lahad, M. Kango-Singh, K. H. Lu, C. L. Warneke, E. N. Atkinson, et al. Atypical PKC{iota} contributes to poor prognosis through loss of apical-basal polarity and Cyclin E overexpression in ovarian cancer PNAS, August 30, 2005; 102(35): 12519 - 12524. [Abstract] [Full Text] [PDF]

				G. D'Andrilli, C. Kumar, G. Scambia, and A. Giordano Cell Cycle Genes in Ovarian Cancer: Steps Toward Earlier Diagnosis and Novel Therapies Clin. Cancer Res., December 15, 2004; 10(24): 8132 - 8141. [Abstract] [Full Text] [PDF]

				A. Bali, P. M. O'Brien, L. S. Edwards, R. L. Sutherland, N. F. Hacker, and S. M. Henshall Cyclin D1, p53, and p21Waf1/Cip1 Expression Is Predictive of Poor Clinical Outcome in Serous Epithelial Ovarian Cancer Clin. Cancer Res., August 1, 2004; 10(15): 5168 - 5177. [Abstract] [Full Text] [PDF]